Large-scale, placebo-controlled trials established that nonsteroidal anti-inflammatory drugs confer a cardiovascular hazard: this has been attributed to depression of cardioprotective products of cyclooxygenase (COX)-2, especially prostacyclin. An alternative mechanism by which nonsteroidal anti-inflammatory drugs might constrain cardioprotection is by enhancing the formation of methylarginines in the kidney that would limit the action of nitric oxide throughout the vasculature.
C yclooxygenases (COX)-1 and -2 are constitutively expressed in the kidney and contribute to the regulation of renal function.
1,2 COX-1 is expressed in collecting ducts, arteriolar endothelial cells (ECs), mesangial cells, and epithelial cells of the Bowman capsule; COX-2 expression is localized to the macula densa, epithelial cells lining the ascending loop of Henle, and the medullary interstitial cells of the renal papillae. 3 However, COX-2 may be expressed in response to inflammatory stimuli in many different cell types within the kidney. 4 Prostanoids produced by both COX isozymes are involved in regulating vascular tone, glomerular filtration, electrolyte and water balance regulation, and renin release. 5 Nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit the activity of the more constitutive cyclooxygenase COX-1 and the more inducible COX-2, are effectively used to relieve pain, inflammation, and fever. However, their use is associated with an increased risk of gastrointestinal, cardiovascular, and renal adverse effects.
Traditional NSAIDs, such as ibuprofen and naproxen, inhibit both COX isozymes, rate-limiting enzymes that are involved in the biotransformation of arachidonic acid into prostanoids. These include prostaglandin (PG) E 2 , PGD 2 , PGF 2α , prostacyclin (PGI 2 ), and thromboxane. Selective COX-2 inhibitors, such as rofecoxib and celecoxib (coxibs), were developed to reduce the incidence of serious gastrointestinal events, but are more likely to cause serious cardiovascular and renal events than nonselective traditional NSAIDs . 6 The use of all NSAIDs has been associated with dosedependent renal side effects. 7 Many of the side effects are reversible on NSAID withdrawal. However, chronic use of NSAIDs may also result in end-stage chronic renal disease, particularly in patients with other risk factors or on other nephrotoxic drugs.
Any change in renal function may influence the cardiovascular system; hence, alterations in hemodynamic stability and renal function by NSAIDs may also contribute to their cardiovascular side effects. 8 A novel link between renal COX-2 inhibition and vascular dysfunction caused by NSAID use has been recently proposed. 9 Ahmetaj-Shala et al 9 reported that COX-2 deletion or inhibition modified the generation of kidney-derived methylarginines and consequently adversely influenced the systemic vasculature by restraining the protective effects of nitric oxide (NO).
Methylarginines (N-mono-methylarginine [L-NMMA], asymmetrical dimethylarginine [ADMA] , and symmetrical dimethylarginine [SDMA] ) are intracellular amino acids formed during posttranslational methylation of arginine by methyltransferases. ADMA and L-NMMA, but not SDMA, are competitive inhibitors of all 3 forms of NO synthase enzymes, thus limiting NO bioavailability. 10 Because circulating ADMA is present at higher concentrations than L-NMMA, ADMA is considered to be the principal endogenous inhibitor of NO synthase activity. 11 Elevated ADMA levels in plasma have been associated with risk factors for cardiovascular disease. ADMA levels are quantitative predictors of adverse cardiovascular outcomes. 12, 13 AhmetajShala et al 9 reported high plasma levels of ADMA, and sometimes of L-NMMA, in conventional Cox-2-deficient mice; in mice treated with parecoxib, a selective COX-2 inhibitor; in mice lacking prostacyclin receptor (Ip); and in healthy volunteers treated with celecoxib or naproxen. 9 Based on these observations, it was proposed that druginduced elevation of methylarginines might explain the cardiotoxicity of NSAIDs and that plasma ADMA might serve as a biomarker of such events.
Here, using multiple genetic and pharmacological approaches to disrupt the COX-2 pathway in mice and analyzing plasma from patients taking NSAIDs, we did not observe an increase in methylarginines. By contrast, we did observe an increase in plasma ADMA in mice rendered hypertensive by infusion of angiotensin II (Ang II) at a dose that caused renal impairment, as has previously been reported.
14 Interestingly, after a 4-week washout period after the infusion of Ang II, blood pressure, plasma creatinine, and ADMA levels all
Clinical Perspective
What Is New?
• Elevated plasma asymmetrical dimethylarginine (ADMA) was reported when cyclooxygenase (COX)-2 is deleted before birth or inhibited with nonsteroidal anti-inflammatory drugs in mice and healthy volunteers. In these settings, COX-2 deletion or inhibition was associated with kidney dysfunction.
• Here we show that, in diverse settings of COX-2 depletion or inhibition in mice and in humans, ADMA is unaltered in the presence of normal renal function as reflected by plasma creatinine.
• ADMA and creatinine levels are elevated together when blood pressure is elevated by angiotensin II in mice subject to COX-2 inhibition. ADMA falls to normal, as does renal function, after washout of angiotensin II.
What Are the Clinical Implications?
• The previous report of elevated ADMA reflected impaired renal function rather than a direct consequence of COX-2 deletion or inhibition.
• ADMA could be elevated by nonsteroidal antiinflammatory drugs in the setting of renal dysfunction. However, even in such patients, the clinical consequences of this modest increase remain to be determined.
• The most plausible mechanism by which nonsteroidal anti-inflammatory drugs confer a cardiovascular hazard is by suppression of COX-2-derived cardioprotective prostaglandins, particularly prostacyclin.
fell to normal levels. Celecoxib-treated mice also exhibited increased ADMA and plasma creatinine in response to infusion of Ang II, and their levels also returned to normal thereafter. Given that conventional Cox-2 knockout (KO) mice have impaired kidney function and the NSAID regimens used in mice and patients in the previous study elevated serum creatinine, it seems likely that the reported elevation in ADMA reflected renal dysfunction rather than a direct consequence of COX-2 deletion or inhibition.
METHODS
The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure by contacting the corresponding author.
The mass spectrometry and metabolomics data are deposited in MetaboLight database (www.ebi.ac.uk/metabolights). The raw metabolomics data are available under accession No. MTBLS680, and the raw mass spectrometry data are available under accession No. MTBLS685.
Human Subjects
Peripheral blood from donors with osteoarthritis was obtained through the Partners HealthCare Biobank, a repository of serum and plasma samples from patients who consented to link their medical records with samples for research purposes, at Partners HealthCare (Massachusetts General Hospital and Brigham and Women's Hospital), according to institutional review board-approved protocols. We identified patients with osteoarthritis by filtering for those with osteoarthritis billing codes and plain radiographs of the hips or knees. To reduce the potential for confounding by other comorbidities, we excluded patients with any billing codes for diabetes mellitus, rheumatoid arthritis, cancer, or coronary artery disease. Among this set, we used natural language processing techniques in the clinical notes to identify patients who were never smokers. We restricted the sample to those who were not obese. Among this set, we identified NSAID users by prescription queries (n=174) and those who never received any NSAID prescription. We performed directed chart review to identify patients with strong evidence of a prescription NSAID around the date of blood draw (n=51). NSAID exposure was confirmed by mass spectrometry assays in these samples (n=31). Some of them (n=16) presented therapeutic levels of NSAIDs and were used as NSAID case status. Controls were defined using electronic health record data restricted to the 12 months before blood draw as (1) osteoarthritis patients without any NSAID prescription and (2) with no evidence of text mention of NSAIDs using natural language processing. Controls (n=97) had mass spectrometry assays performed, and those who had no NSAID detectable were considered controls for analyses (n=16).
Human Blood Urea Nitrogen and Creatinine Measurements
Human blood urea nitrogen and creatinine levels were measured in plasma using a standard automated chemistry analyzer.
Animals
All animal studies were performed in accordance with the guidelines approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania. All mice were on a C57/BL6 background unless otherwise specified. Because we observed a gender difference in the plasma and kidney metabolomes, only male mice, 8 to 20 weeks of age, were used for all experiments.
Tamoxifen-inducible Cox-2 KO (ind.Cox-2 KO) mice and their littermate controls (wild-type [WT]) were generated as previously reported. 15 Hyperlipidemic vascular Cox-2 KO (vascular smooth muscle cell [VSMC]/EC Cox-2 Ldlr KO) mice and their control (Ldlr KO) mice were generated as previously reported. 16 Ip KO mice 17 were bred in a homozygous manner, and C57/BL6 mice were used as controls.
All animals were fed ad libitum with regular chow diet, unless specified, for the course of study. Mice were kept under a 12-h light/12-h dark cycle.
Study Design

Ind.Cox-2 KO Study
Systolic blood pressure was measured in conscious 16-weekold ind.Cox-2 KO mice and WT by a tail-cuff system. Blood was collected from the vena cava, and then plasma was analyzed for l-arginine, methylarginines, and creatinine levels or for metabolomics analysis. Kidney cortex and medulla from ind.Cox-2 KO were harvested as described previously 9 and used for real-time polymerase chain reaction analysis of gene expression and for metabolomics analysis.
Celecoxib and Rofecoxib Study
Twelve-week-old C57/BL6 mice started receiving a diet containing celecoxib (100 mg/kg body weight [BW] per day) or rofecoxib (50 mg/kg BW per day) for 8 weeks. Celecoxib and rofecoxib were obtained from Sequoia Research Products. Drug-containing diets were prepared by Teklad laboratory. Systolic blood pressure was measured in conscious mice at the end of the study by a tail-cuff system. Blood was collected from the vena cava and, after centrifugation, plasma was analyzed for l-arginine, methylarginines, and creatinine levels by mass spectrometry and for metabolomics analysis. Kidney cortex and medulla were harvested and used for realtime polymerase chain reaction analysis of gene expression.
Ang II Study
Ind.Cox-2 KO, WT, and C57/BL6 mice (on a control diet or a celecoxib diet for 3 weeks) at 12 to 14 weeks of age received Ang II (1500 µg/kg per day, Calbiochem, Darmstadt, Germany) in saline by continuous infusion for 2 weeks. The celecoxib diet was continued during the Ang II infusion but not during the washout period. Ang II was administered subcutaneously via Alzet osmotic minipumps (model 2002) as described previously. 18 In ind.Cox-2 KO mice and WTs, systolic blood pressure was measured in conscious mice at baseline (before Ang II administration) and at the end of the study (2 weeks after starting Ang II infusion) with a computerized noninvasive tail-cuff system and calculated as described previously. 19 In C57/BL6 mice on a control or celecoxib diet, systolic blood pressure was measured at baseline, 2 weeks after
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starting the Ang II infusion, and 4 weeks after the end of the Ang II infusion using a tail-cuff system. Plasma was analyzed for l-arginine, methylarginines, and creatinine levels by mass spectrometry.
Parecoxib Study
Twelve-to 14-week-old C57/BL6 mice received parecoxib sodium (100 mg/kg; Sequoia Research Products) in drinking water for 4 days as previously reported. 9 Systolic blood pressure was measured in conscious mice at baseline (before starting parecoxib administration) and at the end of the study by radiotelemetry. Plasma was analyzed for l-arginine, methylarginines, and creatinine levels. Urine samples were collected at the end of the study using metabolic cages and were analyzed for prostanoids and creatinine levels. All measurements were by mass spectrometry.
Ip KO Study
Blood was collected from the vena cava from 8-to 10-weekold Ip KO mice and WT. Plasma samples were analyzed for l-arginine, methylarginines, and creatinine levels by mass spectrometry.
Blood Pressure Measurement by Radiotelemetry
The implantation of radiotelemetry (model No. TA11PA-C20, Data Sciences International, St. Paul, MN) was performed as previously described. 20 After 1 week of recovery, blood pressure was monitored continuously using the Dataquest LabPRO Acquisition System.
Real-Time Polymerase Chain Reaction Analysis of Gene Expression
Total RNA from kidney samples was isolated using the Qiagen RNeasy Kit. Reverse transcription was performed using an RNA-cDNA kit (Applied Biosystems, Carlsbad, CA). Real-time polymerase chain reaction was performed using ABI Taqman primers and reagents on an ABI Prism 7500 thermocycler according to the manufacturer's instructions. The following primers were used: Cox-2 (Mm00478374_m1), Cox-1 (Mm00477214_m1), Prmt1 (Mm00480133_m1), Agxt2 (Mm01304088_m1), Ddah1 (Mm01319453_m1), and Ddah2 (Mm00516768_m1). All mRNA measurements were normalized to Gapdh (Mm99999915_g1) mRNA levels.
Mass Spectrometric Analysis of Prostanoids
Urinary prostanoid metabolites were measured by liquid chromatography/mass spectrometry as previously described. 20 Mouse urine samples were collected by using metabolic cages over an 8-hour period. Results were normalized with urinary creatinine.
Mass Spectrometric Analysis of Plasma or Urinary Creatinine
Quantitation of plasma or urinary creatinine was performed using ultra high pressure liquid chromatography/tandem mass spectrometry with positive electrospray ionization and multiple reaction monitoring. Stable isotope-labeled internal standard (1 mL, 2.5 μg/mL [d3]-creatinine in 3% water/acetonitrile) was added to 10 μL of mouse plasma or 20 μL of mouse urine. A Shimadzu Prominence Ultra-Performance Liquid Chromatography (UPLC) system was used for chromatography. The UPLC column was 2.1×50 mm with 2.5-μm particles (Waters XBridge BEH HILIC). The Thermo Finnigan TSQ Quantum Ultra tandem instrument (Thermo Fisher Scientific) equipped with a triple quadrupole analyzer was operated in positive-mode electrospray ionization, and the analyzer was set in the multiple reaction monitoring mode for the analysis of creatinine. The transitions for creatinine was 114>86. Quantitation was done by peak area ratio, and results were normalized to the sample volume.
Mass Spectrometric Analysis of NSAID Plasma Levels
For the plasma concentrations of acetaminophen, celecoxib, naproxen, diclofenac, ibuprofen, indomethacin, rofecoxib, or salicylic acid, samples were spiked with internal standards and purified by solid-phase extraction. The analysis was performed on a Waters ACQUITY UPLC system in-line with a Waters Xevo TQ-S Triple Quadrupole Mass Spectrometer. The UPLC system directly interfaced with the positive-mode electrospray ionization source of the mass spectrometer using multiple reaction monitoring. The transitions for salicylic acid were 136.6>93.0, for d4-salicylic acid were 140.6>97.0, for acetaminophen were 150.0>107.1, for d3-acetaminophen were 153.0>107.1, for ibuprofen were 205.3>161.2, for d3-ibuprofen were 208.3>164.2, for naproxen were 229.0>170.1, for d3-naproxen were 232.0>173.1, for diclofenac were 293.8>250.1, for d4-diclofenac were 297.8>254.1, for indomethacin were 355.9>311.9, for d4-indomethacin were 359.9>315.9, for celecoxib were 380.0>316.2, for d7-celecoxib were 387.0>323.2, for rofecoxib were 315>269, and for d5-rofecoxib were 320>273. All were monitored in negative mode. Quantitation was done by peak area ratio, and results were normalized to the sample volume.
Metabolomic Analysis of Kidney and Plasma Samples
Metabolites were extracted using the methanol/chloroform/ water method described previously. 21, 22 Briefly, 100 μL of plasma or 50 µg of tissues was added to 600 μL methanol/ chloroform/water (2:2:1; vol/vol), and the samples were homogenized with a Tissuelyser (Qiagen, UK) for 5 minutes at a frequency of 20/s and sonicated for 15 minutes. Water and chloroform (each of 200 μL) were added to the samples before being centrifuged at 13 300 rpm for 20 minutes. The resulting aqueous and organic phases were separated from the protein pellets. The extraction procedure was repeated on the remaining protein pellets. Both organic and aqueous phases were collected and evaporated to dryness. The dried samples were stored at −80°C until further analysis.
Half of the aqueous extract was reconstituted in 200 μL of 10 mmol/L ammonium acetate containing universally ORIGINAL RESEARCH ARTICLE autosampler was set to 7°C. The mobile phase consisted of solvent A: 0.1% formic acid in HPLC grade water (SigmaAldrich) and solvent B: 0.1% formic acid in acetonitrile (SigmaAldrich). When eluting the column, the following gradient was used: initial conditions were 100% A held for 1.5 minutes followed by a linear gradient with increase of B to 100% at 4.5 minutes with re-equilibration for 1.5 minutes, giving a total run time of 6 minutes with a flow rate of 400 μL/min. The injection volume was 2 μL. Samples were analyzed using a multiple reaction monitoring approach. The ionization mode used by the mass spectrometer was electrospray ionization with a capillary voltage of 3.5 kV for positive ion mode and 2.5 kV for negative ion mode. All compound dependent parameters were established using the Quantiva automatic optimization protocol infusion with standards of the relevant compounds.
For quantitative analysis, acquired data were processed with Xcalibur 2.0 (Thermo Fisher Scientific). Peaks of each analyte and internal standard were detected and integrated. Each analyte was normalized to the internal standard. Fifty-six analytes were measured in plasma, and 66 analytes were measured in tissue (Tables I and II in 
Quantification of l-Arginine and Methylarginines
l-Arginine and methylarginines were quantified using liquid chromatography tandem mass spectrometry. Briefly, 2 internal standards (deuterium [d7]-labeled ADMA, Cambridge Isotope Laboratories, and 13 C6-labeled l-arginine) were added to 50 µL of biological samples (mouse or human plasma) before precipitation in 2:1 volumes of methanol/chloroform. After 15 minutes of sonication, 100 µL of water and 100 µL of chloroform were added and the samples centrifuged (13 300 rpm for 7 minutes at 4°C). Next, 200 µL of the supernatant was vacuum-dried for 2 hours using a refrigerated vacuum dryer and the residue resuspended in 10:90 water/acetonitrile for analysis. Liquid chromatography tandem mass spectrometry was performed using a Waters Xevo-TQ-Smicro mass spectrometer coupled to an Acquity UPLC chromatography system. A Waters BEH Amide column was used, and the mobile phase consisted of solvent A, 95:5 HPLC water/acetonitrile, 2 mmol/L ammonium acetate, and 0.2% formic acid; and solvent B, 90:10 HPLC acetonitrile/water, 2 mmol/L ammonium acetate, and 0.2% formic acid. When eluting the column, the following gradient was used: initial conditions were 100% B with a linear increase of A to 79.4% at 15.5 minutes and at 100% at 15.5 minutes. Conditions were kept with A at 100% until 20.5 minutes, with a return to 100% B at 22 minutes, which was kept until 30 minutes. The initial flow rate was 0.35 mL/min, lowered to 0.3 mL/min between 15.50 and 23.50 minutes, and raised to 0.5 mL/min between 25 and 30 minutes. The mass spectrum parameters were as follows: ADMA, mass-to-charge ratio (m/z): 203. 17 
Statistical Analysis
Unless otherwise indicated, between-group comparison was performed using the nonparametric Mann-Whitney test or nonparametric 1-way ANOVA. All the comparisons were made between animals of the same age and sex on the same genetic background. Spearman correlation was used to relate plasma creatinine to ADMA levels. Results of the statistical analyses of metabolomics data were corrected for multiple testing within each tissue/experiment by the BenjaminiHochberg procedure, as implemented by the p.adjust function in R. Heatmaps were generated in R using the ggplot2 package. 23 The abundances of each metabolite were mapped to a common scale in each heatmap as follows: first, the means and SDs of abundances across all samples were calculated separately for each metabolite. Second, the mean abundances across samples within each experimental group (ie, control, celecoxib-treated, rofecoxib-treated, WT, iCox-2 KO) were calculated separately for each metabolite. Third, these experimental group means were normalized into Z scores by subtracting the all-sample means and dividing the result by the all-sample SDs. Again, this procedure was performed separately for each metabolite. For display purposes, any Z scores >2 or ≤2 were set to 2 and −2, respectively.
RESULTS
Effect of Postnatal Cox-2 Deletion on the Plasma and Kidney Metabolomes
We injected iCox-2 KO male mice and WT with tamoxifen at 8 weeks of age 15 and performed the metabolomics experiments at 16 to 20 weeks.
Cox-1 expression remained unchanged, whereas Cox-2 expression was significantly reduced 15-fold in the medulla and 8-fold in the cortex in the iCox-2 KO mice ( Figure 1A and 1B) . The metabolomic profile of plasma, medulla, and cortex did not reveal significant changes between WT and iCox-2 KO mice ( Figure 1C-1E ). Postnatal Cox2 deletion caused an upregulation of Ddah1in the medulla but not of other genes (Prmt1, Agxt2, and Ddah2) of the l-arginine/NO pathway in the kidney medulla or cortex ( Figure IA -ID in the online-only Data Supplement), and the levels of plasma methylarginines were similar in WT and iCox-2 KO mice ( Figure  IE -IH in the online-only Data Supplement). Methylarginines in the cortex and medulla also did not differ between WT and iCox-2 KO mice ( Figure 1D and 1E) .
These latter observations were replicated in an independent cohort of mice of the same age ( Figure I I-IL in the online-only Data Supplement).
In contrast to the renal impairment in conventional Cox-2 KO mice, 24 plasma creatinine level, a measure of kidney function, did not differ between WT and iCox-2 KO mice (0.621±0.071 and 0.684±0.108 creatinine µg/mL plasma, respectively, in WT and iCox-2 KO mice, mean±SEM, n=5-7). Basal systolic blood pressure was also similar in WT (118.8±2.2 mm Hg, mean±SEM, n=6) and iCox-2 KO mice (116.8±3.8 mm Hg, mean±SEM, n=4). 
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Effect of Selective COX-2 Inhibition on the Plasma and Kidney Metabolomes
The plasma metabolomic profile was characterized in WT mice that received control, celecoxib (100 mg/kg BW per day), or rofecoxib diets (50 mg/kg BW per day) for 2 months before they were euthanized. These drug regimens cause selective inhibition of COX-2 in vivo 19, 25 and result in therapeutic drug plasma concentrations (0.74±0.24 µmol/L and 0.53±0.03 µmol/L, respectively, for celecoxib and rofecoxib; mean±SEM, n=5). Furthermore, plasma creatinine did not differ between the groups (0.22±0.05, 0.52±0.32, 0.28±0.04 creatinine/glutamate, respectively, in control, celecoxib, and rofecoxib groups; mean±SEM, n=5). Similarly, systolic blood pressure was not altered by treatment with celecoxib and rofecoxib (112.2±4.4, 115.2±4.9, 117.8±2.1 mm Hg, respectively, in control, celecoxib, and rofecoxib groups; mean±SEM, n=5). 
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Neither drug altered COX-1 expression in the kidney cortex or medulla, but they both increased Cox-2 expression in the cortex (Figure 2A and 2B) . The metabolomic profile of plasma did not reveal significant changes between the 3 groups ( Figure 2C ). Moreover, celecoxib and rofecoxib did not have an impact on the expression of genes of the l-arginine/NO pathway in the kidney medulla and cortex ( Figure IIA-IID 
Effect of Parecoxib on Methylarginines
The treatment of mice with parecoxib (100 mg/kg BW per day) for 4 days caused selective inhibition of COX-2 as reflected by a significant reduction of prostacyclin, an index of COX-2 activity (2.9±0.3 and 2.1±0.1 prostacyclin ng/mg creatinine, respectively, in vehicle and parecoxib groups; mean±SEM, n=4-5; *P<0.05; Figure 3A ), but no effect on thromboxane, an index of COX-1 activity (21.26±3.13 and 22.22±1.68 thromboxane ng/mg creatinine, respectively, in vehicle and parecoxib groups; mean±SEM, n=4-5; Figure 3B ). In the same setting, parecoxib had no significant effect on systolic blood pressure in the active phase (129.4±13.7 and 118.3±9.3 mm Hg, respectively, in vehicle and parecoxib groups; mean±SEM, n=4-5) or in the resting phase (105.9±8.2 and 100.3±8.6 mm Hg, respectively, in vehicle and parecoxib groups; mean±SEM, n=4-5; Figure 3C ). As seen with celecoxib and rofecoxib, COX-2 inhibition induced by parecoxib did not alter plasma arginine 
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and methylarginines levels ( Figure 3D-3G ) or plasma creatinine (1.15±0.15 and 0.98±0.15 µg/mL creatinine, respectively, in control and parecoxib treated mice; mean±SEM, n=4-5).
Effect of Ang II-Induced Hypertension on Methylarginines in Mice
Infusion of Ang II for 2 weeks caused a significant increase in systolic blood pressure that reverted to baseline after a 4-week washout period in the control but not in celecoxib-treated mice (106.1±6.5, 146.4±6.4, and 107.2±6.4 mm Hg, respectively, at baseline, 2, and 6 weeks after Ang II in control group; mean±SEM, n=5-9; Figure 4A ; 104.3±3.4, 154.4±6.2, and 119.6±3.6 mm Hg, respectively, at baseline, 2, and 6 weeks after Ang II in celecoxib group; mean±SEM, n=3-7; Figure 4B ). Plasma ADMA (82.3±3.9, 117.4±5.9, and 89.1±5.3 nmol/L, respectively, at baseline, 2, and 6 weeks after Ang II in control group, mean±SEM, n=5-12, and 89.0±6.2, 109.5±3.8, and 82.5±8.5 nmol/L, respectively, at baseline, 2, and 6 weeks after Ang II in celecoxib group, mean±SEM, n=3-15; Figure 4C and 4D) and plasma creatinine (0.60±0.02, 0.91±0.07, and 0.60±0.06 µg/ mL plasma, respectively, at baseline, 2, and 6 weeks after Ang II in control group, mean±SEM, n=5-12, and 0.61±0.03, 1.12±0.11, and 0.53±0.06 nmol/L, respectively, at baseline, 2, and 6 weeks after Ang II in celecoxib group, mean±SEM, n=3-15; Figure 4E and 4F) levels were elevated by the infusion with Ang II and returned to normal levels after the washout period in both control and celecoxib-treated mice. We observed a positive correlation between plasma creatinine and ADMA levels ( Figure III in the online-only Data Supplement).
Effect of Postnatal Cox-2 Deletion on Methylarginines in Hypertensive Mice
Ind.Cox-2 KO mice and their littermate controls were made hypertensive by Ang II infusion for 2 weeks. The increase in systolic blood pressure was not different between WT and ind.Cox-2 KO mice after Ang II infusion (153.8±5.5 and 143.1±6.0 mm Hg, respectively, in control and ind.Cox-2 KO mice; mean±SEM, n=6). The levels of l-arginine and methylarginines in hypertensive mice were unaltered by genotype ( Figure 5A-5D ). Moreover, there was no difference in plasma creatinine level between WT and ind.Cox-2 KO mice after Ang II infusion (1.177±0.122 and 1.185±0.119 µg/mL plasma, respectively; mean±SEM, n=6).
Effect of Vascular Cox-2 Deletion on Methylarginines
Male mice lacking Cox-2 in vascular cells (VSMC/EC Cox-2 Ldlr KO) on a high-fat diet for 3 months had elevated systolic blood pressure compared with Ldlr KO controls. 16 Plasma creatinine levels were ≈10% lower Circulation. Figure 6A -6D.
Effect of Ip Deletion on Methylarginines
Unperturbed mice lacking Ip are normotensive and do not develop spontaneous thrombosis, although they are sensitive to thrombogenic and hypertensive stimuli. 25, 26 Deletion of the Ip had no effect on the plasma levels of l-arginine and methylarginines ( Figure 7A-7D) or on plasma creatinine (0.861±0.065 and 0.888±0.052 µg/mL creatinine, respectively, in male WT and Ip KO; mean±SEM, n=3) in these mice. 
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Effect of NSAID Exposure on Methylarginines in Osteoarthritis Patients
We characterized methylarginines (ADMA, L-NMMA, and SDMA) in the plasma samples of male osteoarthritis patients obtained from the Partners HealthCare Biobank. We sought their exposure to NSAIDs by measuring the plasma concentration of the 7 most commonly consumed NSAIDs (acetaminophen, celecoxib, naproxen, diclofenac, ibuprofen, indomethacin, naproxen, and salicylic acid) by mass spectrometry. We identified 16 patient plasma samples that contained therapeutic levels of ≥1 NSAIDs (1 acetaminophen, 2 acetaminophen+aspirin, 1 acetaminophen+celecoxib, 1 acetaminophen+ibuprofen, 7 naproxen, 2 naproxen+aspirin, 1 naproxen+ibuprofen, 1 diclofenac) and 16 patients with clinically comparable disease that were not exposed to NSAIDs (Table III in the  online-only Data Supplement) . Consistent with our data in mice, the treatment with NSAIDs in these osteoarthritis patients with normal renal function, as reflected by plasma creatinine and blood urea nitrogen, did not alter plasma levels of larginine or methylarginines (Table) .
DISCUSSION
Large-scale, placebo-controlled trials established that NSAIDs selective for inhibition of COX-2 confer a cardiovascular hazard. 6 Deep phenotyping studies of drug response in humans and both genetic and pharmacological perturbation of the COX-2 pathway in mice reveal that suppression of cardioprotective prostaglandins, such as PGI 2 and PGE 2 , affording a mechanistic explanation for this hazard. 19 Depletion of COX-2 in vascular cells in mice increases their response to thrombogenic and hypertensive stimuli coincident with depression of PGI 2 biosynthesis as reflected by urinary prostacyclin. 20 Similarly, depression of the same urinary biomarker in the absence of coincident platelet inhibition by treatment with celecoxib or rofecoxib in humans underlay the initial prediction of the cardiovascular adverse effects of NSAIDs. At the outset, it was suggested that other endogenous cardioprotective mechanisms, such as the vascular elaboration of NO, might compensate for the reduction in PGI 2 . However, various manipulations that disrupted the COX-2/PGI 2 /IP synthesis/response pathway yielded adverse cardiovascular phenotypes. 15, 17, [26] [27] [28] Furthermore, depletion of COX-2 in vascular cells yielded the surprising observation that endothelial NO synthase expression was regulated by COX-2-dependent PGI 2 formation. 20 The depression of vascular NO release with COX-2 depletion could be rescued with a PGI 2 analog. Thus, rather than NO compensating for the vascular consequence of inhibiting PGI 2 formation, reduced expression of en- ORIGINAL RESEARCH ARTICLE dothelial NO synthase is a secondary effect, likely to amplify the consequence of COX inhibition. 20 Recently, an alternative mechanism by which NSAIDs might constrain cardioprotection by NO has been proposed-drug-dependent enhanced formation of methylarginines in the kidney that would limit the action of NO throughout the vasculature. 9 Several approaches were taken to address this hypothesis, including the detection of elevated methylarginines and, in some cases, elevated expression of genes of the l-arginine/NO pathway, in conventional Cox-2 KO mice, in mice administered the selective COX-2 inhibitor parecoxib, and in healthy volunteers treated with NSAIDs. Elevated methylarginines were associated with impaired vascular relaxation ex vivo in conventional Cox-2 KOs and a reduction in the difference in blood pressure between the active and resting phases in parecoxib-treated mice. Based on these observations, it was proposed that drug-induced elevation of methylarginines might explain the cardiotoxicity of NSAIDs and that plasma ADMA might serve as a biomarker of such events. However, COX-2 plays an important role during development and conventional Cox-2 KO mice exhibit myocardial fibrosis, hypertension, and glomerulosclerosis. 26, 27 Although plasma creatinine was not reported in the experiments using parecoxib, plasma creatinine was elevated in this study in the conventional Cox-2 KO mice, in the Ip KO mice, and in the healthy volunteers consuming NSAIDs who exhibited the elevation in methylarginines.
To address the hypothesis that the increase in methylarginines reflected diminished renal clearance rather than a direct consequence of drug action, we studied the broader plasma and renal metabolome in iCox-2 KO mice and VSMC/EC Cox-2 Ldlr KO mice, both of which exhibit normal renal function. We also exposed mice to therapeutic concentrations of rofecoxib, celecoxib, and parecoxib, none of which altered renal function as reflected by plasma creatinine or elevated basal blood pressure. Finally, we sought evidence for an elevation in plasma methylarginines in osteoarthritis patients with confirmed exposure to NSAIDs that inhibit COX-1 and COX-2. In these diverse settings of COX-2 depletion or inhibition, but in the presence of normal renal function as reflected by plasma creatinine, we found no systematic impact on blood pressure, plasma arginine, or methylarginines or on the expression of genes (Prmt1, Agxt2, and Ddah2) of the l-arginine/NO pathway in the renal medulla or cortex in the mice. By contrast, elevating blood pressure in WT mice by infusing Ang II impaired renal function and elevated plasma ADMA as previously described.
14 Interestingly, after a 4-week washout period of Ang II, blood pressure, plasma creatinine, and ADMA levels were restored to normal levels. Celecoxib-treated mice also had elevated ADMA and plasma creatinine levels in response to infusion of Ang II, but these levels fell to normal after washout. The lack of a direct effect of celecoxib on ADMA is consistent with data recently reported in an experimental model of rheumatoid arthritis. 29 Thus, in the setting of normal plasma creatinine, we were unable to detect an increase in plasma methylarginines consequent to COX-2 deletion or inhibition. It seems likely that the observations of Ahmetaj-Shala et al 9 reflect the renal compromise evident in conventional Cox-2 KO mice, in their Ip KO mice, and in the healthy volunteers consuming NSAIDs that they studied. Indeed, consistent with this likelihood, we observed a positive correlation between plasma creatinine and ADMA levels in the present studies. The dominant mechanism by which NSAIDs confer a cardiovascular hazard is by depression of cardioprotective products of COX-2, especially PGI 2 .
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